

The First Negative Allosteric Modulator for Dopamine D₂ and D₃ Receptors

SB269652 May Lead to a New Generation of Antipsychotic Drugs

Mario Rossi, Irene Fasciani, Francesco Marampon, Roberto Maggio, Marco Scarselli

Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, United States (M.R)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy (I.F., F.M., R.M.)

Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy (M.S.)

RUNNING TITLE PAGE

Running title: Allosteric modulators as new generation antipsychotics

Address correspondence to:

Roberto Maggio, Department of Biotechnological and Applied Clinical Sciences,

University of L'Aquila, Via Vetoio Coppito 2, 67100 L'Aquila (Italy), Email:

roberto.maggio@univaq.it, or Marco Scarselli, Department of Translational Research

and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Email:

marco.scarselli@med.unipi.it

Number of text pages (32);

Tables (0);

Figures (2);

References (60);

Number of words in the abstract (233);

Number of words in the introduction (767);

Non standard abbreviations: SB269652 = N-((trans)-4-(2-(7cyano-3,4-

dihydroisoquinolin-2(1 H)-yl)ethyl)cyclohexyl)-1 H-indole-2-carboxamide; 7CN-THIQ

= 7-cyano-tetrahydroisoquinoline;

Abstract

D₂ and D₃ dopamine receptors belong to the largest family of cell surface proteins in eukaryotes, the G protein-coupled receptors (GPCRs). Considering their crucial physiological functions and their relatively accessible cellular locations, GPCRs represent one of the most important classes of therapeutic targets. Until recently, the only strategy to develop drugs regulating GPCR activity was through the identification of compounds that directly acted on the orthosteric sites for endogenous ligands. However, many efforts have recently been made in order to identify small molecules that are able to interact with allosteric sites. These sites are less well-conserved; therefore, allosteric ligands have greater selectivity on the specific receptor. Strikingly, the use of allosteric modulators can provide specific advantages, such as an increased selectivity for GPCR subunits and the ability to introduce specific beneficial therapeutic effects without disrupting the integrity of complex physiologically-regulated networks. In 2010, our group unexpectedly found that SB269652, a compound supposed to interact with the orthosteric binding site of dopamine receptors, was actually a negative allosteric modulator of D₂ and D₃ receptor dimers, thus identifying the first allosteric small molecule acting on these important therapeutic targets. This review addresses the progresses in the understanding of the molecular mechanisms of interaction between the negative modulator SB269652 and D₂ and D₃ dopamine receptor monomers and dimers, and also the perspectives of developing new dopamine receptor allosteric drugs based on SB269652 as the leading compound.

Introduction

After more than half a century, dopamine receptors still remain the main target of antipsychotic drugs. The first-generation antipsychotics began in 1952 with the serendipitous discovery that the antihistamine chlorpromazine reversed the symptoms of a severely agitated psychotic male in the military hospital in Paris (Hamon et al., 1952). This was the start of the neuropharmacological revolution (Ban, 2007).

At a later time, second-generation antipsychotics called atypical were introduced in clinical use with a better pharmacological profile, particularly in terms of motor extrapyramidal side effects (Meltzer and Massey, 2011). In addition, they seem to have additional therapeutic properties such as cognitive enhancement and an improvement in the negative symptoms of schizophrenia. In general, the mechanism of action of first-generation antipsychotics is to block dopamine D₂ receptors, while other explanations have been proposed besides D₂ receptors for second generation antipsychotics, mostly involving 5-HT_{1a} and 5-HT_{2a} serotonin receptors, as well as muscarinic, adrenergic, glutamatergic and histamine receptors (Meltzer and Massey, 2011). Among the second-generation antipsychotics, clozapine is considered the “gold standard” for treating schizophrenia (Meltzer, 2012).

In this class of second generation antipsychotics, aripiprazole distinguishes itself from the others with a particular mechanism of action, such as being a partial agonist at D₂ receptor (Keck and McElroy, 2003). However, some authors have questioned this mechanism and have proposed that aripiprazole is a functionally selective antagonist for the D₂/β-arrestin2 interaction and a partial agonist for D₂-induced G-protein activation (Mailman and Murthy, 2010). In addition, interactions with 5-HT_{1a} and 5-HT_{2a} receptors may contribute to its antipsychotic activity (Stark et al., 2007). The synthesis of these two generations of antipsychotic drugs was based on targeting the orthosteric site of dopamine and other GPCRs.

Dopamine receptors belong to the monoaminergic G protein-coupled receptors (GPCRs) family and represent an important pharmacological target for the treatment of schizophrenia and Parkinson's disease (Missale et al., 1998). Five dopamine receptors have been cloned and classified in D_{1like} (D₁ and D₅) and D_{2like} (D₂, D₃ and D₄) receptors that have distinct functions and distributions in the brain and in the periphery.

The dopamine receptor orthosteric site is located deep in the core structure of these receptors. In particular, dopamine binds, with its protonated amino group, to an aspartic acid in the transmembrane region III and with its catechol moiety to serine residues in the transmembrane region V. On this matter, GPCR crystallization has become a crucial step to understanding in detail the structure and dynamics of receptor binding and functioning. Consistent with this notion, the increased number of GPCR crystal structures resolved in recent years has allowed the characterization of mechanisms of receptor activation and led the way to the synthesis of more selective and potent drugs. For example, the recent crystallization of the dopamine D₃ receptor (Chien et al., 2010), which has 76% homology with the dopamine D₂ receptor, has opened the way to the structure-guided development of new dopamine receptor drugs (Keck et al., 2014), and to the characterization of antipsychotic inhibition mechanisms (Salmas et al., 2016).

Amongst the various mechanisms that could explain receptor versatility, homo- and heterodimerization have received general recognition as being responsible for tuning, diversifying and amplifying GPCR signaling, which strongly suggests that very complex interactions take place between ligands and receptor quaternary structures (Maggio et al., 2007; Ferre et al., 2014). Indeed, it has been shown that agonists or antagonists bind to one protomer of a GPCR dimer, altering binding and the functional properties of agonists, or antagonists interacting with the other protomer, which suggests an allosteric type of interaction between the two protomers (Carrillo et al., 2003). Importantly, it has been shown that the three most abundant dopamine receptor subtypes, D₁, D₂ and D₃, form heteromeric

complexes, and that, in functional assays, D₁-D₃, D₁-D₂ and D₂-D₃ heteromers have different signaling properties compared to the respective monomers (Scarselli et al., 2001; Lee et al., 2004; Fiorentini et al., 2008; Aloisi et al., 2011; Pou et al., 2012).

As a matter of fact, another way to target GPCRs is to use allosteric modulators, which are compounds interacting with binding sites that are topographically distinct from the orthosteric site recognized by the receptor's endogenous agonist and have not evolved to accommodate endogenous ligands (May et al., 2007; Rossi et al., 2009). The use of allosteric modulators has specific advantages, such as the increased selectivity for GPCR subunits and the ability to introduce specific beneficial therapeutic effects without disrupting the integrity of complex physiologically-regulated networks. In particular, this review summarizes a new mechanism of allosteric regulation across dopamine receptor dimers and the development of new allosteric drugs for dopamine receptors.

SB269652 is an atypical allosteric modulator for D₂ and D₃ dopamine receptors

Recently, our group has discovered the first negative allosteric modulator for D₂ and D₃ dopamine receptors, the N-((trans)-4-(2-(7cyano-3,4-dihydroisoquinolin-2(1 H)-yl)ethyl)cyclohexyl)-1 H-indole-2-carboxamide (SB269652) (**Figure 1**) (Silvano et al., 2010). This compound was originally synthesized by SmithKline Beecham Pharmaceuticals in an effort to find new selective dopamine D₃ antagonists binding to the orthosteric site of the receptor (Reavill et al., 2000; Stemp et al., 2000). Our group re-evaluated this compound in an effort to find ligands that are able to distinguish between D₂ and D₃ homo- and hetero-receptors. During this re-evaluation, SB269652 was confirmed to have a higher affinity for D₃ compared to D₂ receptors, but importantly, a few SB269652 properties were also identified that eventually led us to the conclusion that this compound was an atypical, negative, allosteric modulator for D₂ and D₃ receptors (Silvano et al., 2010). In particular, in binding assays with Chinese hamster ovary (CHO) transfected cells, SB269652 potently abolished the specific binding of

[³H]nemanopride and [³H]spiperone radio-ligands at the concentrations of [0.2nM] and [0.5nM], respectively. Strikingly though, at concentrations of [³H]nemanopride and [³H]spiperone which were 10 times higher, the specific binding of both radio-ligands was only sub-maximally inhibited, indicating an allosteric behavior of SB269652. In fact, if SB269652 was solely acting at the orthosteric site, increasing concentrations of this compound would have displaced [³H]nemanopride and [³H]spiperone completely, regardless of the concentration of the radioligands.

The orthosteric/allosteric nature of SB269652 for D₃ receptors was also confirmed in functional experiments, in which, at low concentrations of dopamine (1 μM), SB269652 showed its orthosteric nature by potently blocking D₃ receptor-mediated activation of Gα_{i3} and phosphorylation of the extracellular-signal-regulated kinase (ERK)1/2, whereas it showed its negative allosteric nature at higher concentrations of dopamine (10 μM) by submaximally inhibiting the stimulatory effects of dopamine. The same kind of responses were also observed in functional assays with D₂ receptors, in which SB269652 only submaximally suppressed D₂ receptor-mediated stimulation of Gα_{i3} and Gα_{qi5} and phosphorylation of ERK1/2 and Akt at high concentrations of dopamine (Silvano et al., 2010).

The allosteric nature of this compound was also shown by using chimeric D₂/D₃ receptors in which their second extracellular loops were switched between the two dopamine receptors (Silvano et al., 2010). This loop has a pivotal role in binding SB269652 with high affinity, and crystallographic analysis has shown that, together with extracellular loop I and the junction of transmembrane helices I, II, and VII, loop II delimits an allosteric site which may interact with bitopic or pure allosteric ligands (Chien et al., 2010).

Because of the atypical allosteric nature of SB269652, this compound was denoted as an “atypical allosteric modulator” in order to indicate the strange behavior of SB269652 for D₃ and D₂ receptors in binding and functional experiments. Indeed, SB269652 behaves as an orthosteric ligand at low concentrations of the radioligands [³H]spiperone and [³H]nemanopride in binding assays, or at low

concentrations of dopamine in functional assays; however, it acts as an allosteric compound at higher concentrations of the radioligands or dopamine. What causes this unusual behavior was later clarified by Arthur Christopoulos' group (Lane et al., 2014). In particular, they showed that SB269652 was a bitopic compound. Bitopic molecules are typically composed of two pharmacophores bridged by a spacer and characterized by the ability to simultaneously bind to the orthosteric and allosteric sites of the same protomer. The bitopic nature of SB269652 was revealed by fragmenting it. In particular, they generated progressively truncated fragments of the 7-cyano-tetrahydroisoquinoline (7CN-THIQ) moiety of SB269652 that contains the tertiary amine, the part of the molecule that is important for the interaction with the conserved aspartic acid of the amine receptors in the orthosteric site. Contrary to SB269652 whole, all 7CN-THIQ fragments were always able to inhibit dopamine action, in a competitive manner, regardless of its concentration, whereas the other active component of SB269652, the indole-2-carboxamide fragment, inhibited dopamine action in a non-competitive manner. The properties of these fragments were tested in functional and radioligand binding experiments (Lane et al., 2014).

Nevertheless, bitopic ligands should not show allosteric properties because they bind to the orthosteric and allosteric sites simultaneously. In fact, allosteric interactions should change the orthosteric binding pocket environment and consequently affect the ability of orthosteric ligands to bind the orthosteric site of the receptor. For instance, extended-length 4-phenylpiperazine derivatives are known to dock to the orthosteric site with the 4-phenylpiperazine moiety and to an allosteric site with the extended aryl amide moiety, but their interaction at the secondary site does not allosterically modulate their binding to the orthosteric site (Furman et al., 2015). Lane et al. (2014) further extended the description of the mechanism of SB269652 binding, providing that the allosteric action of SB269652 was exerted across dopamine receptor dimers, as depicted in **Figure 1**. Reassuring, SB269652 binds in a bitopic mode to one protomer of a dopamine receptor dimer, the 7CN-THIQ part binds to the orthosteric site and the

indole-2-carboxamide part to the allosteric site. The allosteric effects are then the results of changes in the ability of ligands to bind the orthosteric binding pocket on the other promoter of the dimer. In other words, SB269652 behaves as competitive antagonist with receptor monomers and allosterically across receptor dimers.

This “binding” model clearly explains the atypical behavior of SB269652 in binding and functional experiments at low and high concentrations of radio-ligands or dopamine with D₂ and D₃ receptors. As concentrations of radioligands or dopamine increase, more dimers will be occupied and the allosteric effect of SB269652 will be more evident. Furthermore, as discussed below, agonists promote dopamine receptor dimer formation (Tabor et al., 2016), which might help to unveil the allosteric effects of SB269652 in the functional assays with dopamine.

SB269652 influence on the radioligand dissociation constant reveals additional complexity

Negative and positive allosteric compounds alter ligand association and/or dissociation kinetics (Conn et al., 2009; Maggio et al., 2013). The affinity of a compound for its target is related to its association and dissociation rate constants that is quantified by $K_D = K_{off}/K_{on}$, where K_D represents the equilibrium dissociation constant and K_{off} and K_{on} represent the dissociation and association rate constants, respectively. Consistent with this notion, when an allosteric compound modifies the affinity of a ligand for the orthosteric site, its dissociation and association rate constants must change accordingly. Usually, negative allosteric compounds increase the dissociation rate constant and/or decrease the association rate constant. Strikingly, Silvano et al. (2010) demonstrated that SB269652 does not behave as a common negative allosteric modulation, in fact it largely reduces both radioligand association and dissociation rate constants for D₂ and D₃ receptors (Silvano et al., 2010). A similar effect has been described for the antagonist methoctramine at muscarinic M₂ receptors (Jakubík et al., 2014). Methoctramine is a bitopic compound that competes with orthosteric ligands by simultaneously binding

to both the orthosteric and the allosteric binding sites of the M_2 type muscarinic receptor. In addition, methoctramine is also able to bind, even though with a low affinity, to N-methylscopolamine-occupied receptors by interacting solely with the allosteric binding site of M_2 . However, in this case, the interaction between methoctramine and the orthosteric ligand is allosteric. In particular, in dissociation binding experiments with N-[^3H]methylscopolamine pre-labeled M_2 muscarinic receptors, Jakubick et al. (2014) found that the radioligand was trapped into the orthosteric site of M_2 by methoctramine. SB269652 could indeed be working in the same way: binding to the radioligand occupied receptor solely at the allosteric site and preventing its dissociation. If this is the case, the position of SB269652 in the allosteric site could be different between radioligand-occupied and -unoccupied receptors, and the 7CN-THIQ head group could be oriented to bind other regions of the dopamine receptor according to the receptor occupancy status. This was also suggested by our experiments with chimeric D_2/D_3 receptors, where it was demonstrated that the replacement of the extracellular loop II of D_2 with the same segment from D_3 , greatly increased the inhibition potency of SB269652 against [^3H]nemonapride, while the reverse chimera, D_3 with the second extracellular loop from D_2 , highly reduced the affinity for SB269652 (Silvano et al., 2010). This second extracellular loop in the D_2 and D_3 receptor is divergent. For example, in D_3 there is a negatively charged aspartic acid at the end of the loop (D187) that is replaced in D_2 by an alanine (A188). This aspartic acid residue could form a salt bridge with the basic tertiary amine of the 7CN-THIQ group, stabilizing the SB269652 molecule in an alternative pose. Interestingly, this aspartic acid residue of the D_3 receptor has been shown to play a major role in agonist induced tolerance (Gil-Mast et al., 2013). It seems that after continuous agonist stimulation, D187 forms a salt bridge with histidine 354 in extracellular loop III, supporting the concept that the engagement of D187 by drugs could have a profound effect on receptor conformation and eventually an allosteric effect on orthosteric ligands.

Even though counterintuitive, an alternative explanation is that SB269652 could reduce the dissociation rate constant of the radioligand only across receptor dimers. Nevertheless, this seems unlikely as a biphasic dissociation curve of the radioligands should have been seen inasmuch as only a fraction of the dopamine receptors is in the dimeric form (Tabor et al., 2016). Then the most parsimonious explanation is that SB269652 binds with high affinity in a bitopic mode to unoccupied receptors and exerts a predominant allosteric effect across dimers; furthermore, it could bind with low affinity solely at the allosteric site(s) of occupied receptors reducing ligand dissociation (**Figure 1**). Clearly the ability of SB269652 to bind multiple allosteric sites depending on the D₂ and D₃ receptor occupancy status requires further investigations.

SB269652 as the leading compound that led to the development of new antipsychotic drugs

In order to develop new effective antipsychotic drugs, SB269652 could be exploited in two different ways: 1) to maintain its bitopic effect and improve its affinity and allosteric effect across dimers at D₂ receptors, or 2) to design pure and more potent allosteric drugs starting from its indole-2-carboxamide moiety.

By pursuing the first strategy, Shonberg et al. (2015) synthesized a series of compounds that bind to dopamine D₂ receptors in a bitopic manner but with higher affinity compared to the original ligand SB269652. To this purpose, they focused on modifying the three main parts of SB269652: the 7CN-THIQ, the indole-2-carboxamide moieties and the trans-cyclohexylene linker. They found that the orthosteric “head” groups with small 7CN-THIQ substituents were important to maintain the negative cooperativity of SB269652. Among several substitutions, the hydrogen substitution of the nitrile group (compound 12b in Shonberg et al., 2015, **Figure 2**) resulted in a significant 9-fold increase in functional affinity ($K_B = 87$ nM and 776 nM, for 12b and SB269652, respectively) with no significant change in the allosteric cooperativity. Conversely, substitution of the 7CN-THIQ head group with

chemical structures that are privileged scaffolds for dopamine D₂ receptors resulted in compounds with the highest increase in functional affinity but poor allosteric effect (Shonberg et al., 2015).

These results indicate that the 7CN-THIQ binding to the orthosteric site of D₂ receptor is important for the orientation and binding of the indolcarboxamide to the allosteric site. Even subtle modification of 7CN-THIQ can largely affect the functional affinity and negative allosteric cooperativity of the molecule.

Furthermore, linker length was critical for the allosteric effect of SB269652 analogues. The substitution of the trans-cyclohexylene spacer group with the one containing the 1,3-propylene or a 1,4-butylene resulted in an increase in binding affinity with the maintenance of negative allosteric cooperativity. On the contrary, incorporation of 1,5-pentylene spacer resulted in a compound with pure competitive activity, and further extending the length to 1,5-hexylene spacer restored allosteric pharmacology (compound 18d in Shonberg et al., 2015, **Figure 2**). All of these results taken together suggest the important role of spacers in the reciprocal orientation of the 7CN-THIQ and indole-2-carboxamide groups for the binding to the orthosteric and allosteric sites. This is not surprising if it is considered that such cyclohexylene extension, even though relatively flexible, puts some constraints to the simultaneous binding of the two pharmacophores of SB269652 to the orthosteric and allosteric binding sites. The optimal engagement of the two sites requires a linear orientation of the indole-2-carboxamide moiety with the 7CN-THIQ head group (Lane et al., 2014).

Finally, Shonberg et al. (2015) analyzed the effect of modifications in the indole-2-carboxamide moiety of SB269652. As discussed previously, data from D₂ and D₃ chimeric receptors showed that SB269652 binding region extends from the orthosteric site of D₂ and D₃ dopamine receptors up to an allosteric site delimited by their extracellular loops I and II (Silvano et al., 2010). Successive experiments by Lane et al. (2014) supported this concept as they demonstrated that the cyclohexyl and indolic NH residues of SB269652 bind respectively to valine 91 and glutamic acid 95, located at the extracellular end of

transmembrane region II of the D₂ dopamine receptor conferring the allosteric property to the drug. These two residues are also conserved in the D₃ receptor, and correspond to valine 86 and glutamic acid 95, in the transmembrane region II of D₃. As for the D₂ receptor, these residues play a crucial role in docking and conferring the allosteric properties to SB269652. Because the dopamine D₄ receptor has high homology with the D₂ receptor and the glutamic acid residue (Glu95 in D₄) is conserved, whereas the hydrophobic valine residue is substituted with the aromatic amino-acid phenylalanine, it would be interesting to test whether or not SB269652 loses its allosteric effect on D₄ receptors, in fact, this would shed some light on the importance of each of those amino-acids in SB269652 mediated allosteric effects.

Supporting the concept that the indole-2-carboxamide moiety of SB269652 is important for its allosteric effect, SB269652 analogues whose indolic NH groups were substituted with others unable to generate hydrogen bonds (e.g. 1-methyl-1H-indole-2-carboxamide, 25d in Shonberg et al., 2015, **Figure 2**), lost the ability to allosterically interact with the receptors—even though maintaining and showing an increased functional affinity. In contrast, the replacement of the indole ring with an azaindole group increased its affinity 30-fold while maintaining a negative cooperativity (compound 25f in Shonberg et al., 2015, **Figure 2**).

The second approach in order to generate analogues with an improved “allosterism” was to break down SB269652 into small molecules containing the indole-2-carboxamide group (Mistry et al., 2015). Strikingly, Mistry et al. (2015) showed that, in a series of binding and functional assays, the 1H-indole-2-carboxamide moiety (compound 3 in Mistry et al., 2015, **Figure 2**) behaved as a pure allosteric drug for D₂ receptors, even though its affinity and negative cooperativity were weaker than SB269652 (Mistry et al., 2015). Furthermore, Mistry et al. (2015) showed that this molecule had similar affinity and negative allosteric effects for D₃ dopamine receptors compared to the D₂ receptors, which strongly suggested that the difference in SB269652 affinity for D₂ and D₃ receptors was due to the binding of

the 7CN-THIQ moiety to the orthosteric site of the two receptors (Silvano et al., 2010). Interestingly, Mistry et al. (2015) also found that the 1H-indole-2-carboxamide moiety, in ERK1/2 functional assays reduced not only dopamine potency but also its maximal responses, whereas in dopamine mediated GTP γ S recruitment and cAMP production assays, 1H-indole-2-carboxamide showed only a reduction in dopamine potency (Mistry et al., 2015). This indicates that this ligand is able to modulate dopamine binding to the orthosteric site of the receptor in such a way that not only it reduces dopamine potency but interestingly, depending on the functional assay, reduces dopamine efficacy. Furthermore, they confirmed that the residues valine 91 and glutamic acid 95 on the second extracellular loop of the D₂ receptor were crucial for maintaining the allosteric properties of both the leading compound SB269652 and the 1H-indole-2-carboxamide derivative.

The next step taken by Mistry et al. (2015) was to extend the carboxamide group of the 1H-indole-2-carboxamide moiety by adding a fragment derived from SB269652 that extended away from the indole-2-carboxamide moiety and included a tertiary amine group, N-((trans)-4-(2-(dimethylamino)ethyl)cyclohexyl)-1H-indole-2-carboxamide (compound 9a in Mistry et al., 2015). Interestingly, the modification did not alter the negative allosteric effect of the molecule in functional assays with dopamine; however, in spiperone radioligand-binding assays, the compound behaved as a competitive ligand. This suggests that the protrusion of the molecule into the orthosteric binding site is not sufficient to alter dopamine binding and action, but is sufficient to alter the binding of spiperone, which has a bulkier structure. Moreover, a further extension of the 1H-indole-2-carboxamide moiety transformed these analogues into pure competitive ligands.

Subsequently, Mistry et al. (2015) generated analogues from the 1H-indole-2-carboxamide moiety with bicyclic heteroaromatic ring at the carboxamide N-substituent of the molecule.

A key determinant of affinity for these analogues was the degree of N-substitution of the carboxamide moiety. In particular, the mono-substituted derivatives retained their activity while the di-substituted

derivatives mainly lost it (Mistry et al., 2015). Notably, the linear increased in the size of alkyl substituents (from N-ethyl to N-propyl and to N-butyl) improved both affinity and negative cooperativity, progressively. The N-butyl substituent (compound 11d in Mistry et al., 2015, **Figure 2**) was the compound with the most pronounced profile, which suggests that the alkyl substituents bind to an hydrophobic part of the receptor core. Consistent with this, polar substituents were not active.

Mistry et al. (2015) decided then to test the importance of the indole core of the 1H-indole-2-carboxamide moiety by synthesizing a set of analogues bearing alternative bicyclic heterocyclic cores. Strikingly, compounds unable to form hydrogen bonds did not show any allosteric property, further supporting the concept that the NH group of the indole core binds to the glutamic acid 95 of the D₂ receptor.

Mistry et al. (2015) completed their work by generating a new bitopic ligand that contained all the chemical optimizations that greatly improved the activities of the SB269652 analogues. In particular, compound 11d was incorporated in the bitopic pharmacophore of SB269652 by anchoring it to the 7CN-THIQ group; this resulted in an improved affinity (81 nM) for D₂ receptors and a similar negative allosteric cooperativity compared to its leading compound SB269652 (compound 36 in Mistry et al., 2015, **Figure 2**). It is worth noting that compound 36 is identical to compound 18b from the study by Shoneberg et al. (2015), and, therefore, two independent approaches led to the same optimized compound.

One important aspect of the work of Mistry et al. (2015) that needs to be addressed concerned the allosteric mechanism through which SB269652 analogous operate across D₂ or D₃ receptor dimers. As previously discussed, the allosteric properties of SB269652 might lie in the ability to modify the affinity for orthosteric ligands across D₂ or D₃ receptor dimers. However, as discussed by Mistry et al. (2015), the 1H-indole-2-carboxamide moiety and its derivatives do not require an allosterism across dimer types of interaction in order to function as allosteric modulators. In fact, these compounds do not

have an orthosteric pharmacophore, and are small enough to solely interact with the allosteric site of the receptor and, therefore, to exert allosteric effects within the same receptor protomer (Mistry et al., 2015). Moreover, adding fragments of SB269652 and thus extending the carboxamide group away from the 1H-indole-2-carboxamide moiety, led to a critical extension: the synthesis of the peculiar compound 9a (see above), which remained allosteric only for dopamine but not for spiperone. These two distinctive behaviors of 9a for the two orthosteric ligands strongly suggest that the chemical extension was interfering with the binding of spiperone at the orthosteric site of the same promoter. Otherwise, if 9a allosteric effects were exerted across dimers, the compound would have shown an allosteric effect for spiperone as well. Furthermore, there is evidence that support the concept that many allosteric modulators modify the binding properties of orthosteric ligands at the promoter level instead of across dimers. In particular, Kruse et al. (2013) crystallized the ternary complex structure formed by the allosteric modulator LY2119620 and the orthosteric agonist iperoxo which were simultaneously bound to the muscarinic M₂ receptor (Kruse et al., 2013). The crystal structure showed that LY2119620 binds to a largely pre-formed binding site in the extracellular vestibule of the iperoxo-muscarinic M₂ receptor complex and induces slight contraction of the outer binding pocket of the receptor that profoundly modifies the binding properties of the orthosteric site of the M₂ receptor. Finally, it is worth noting that the indole-2-carboxamide chemical structure of SB269652 is very similar to a recently identified positive allosteric modulator for D₂ and D₃ receptors, suggesting that understanding the binding mechanism of SB269652 to these receptors could lead to the development of both D₂ and D₃ receptor-specific positive and negative allosteric compounds (Wood et al., 2016).

Dopamine receptor dimerization and allosteric effect of SB269652

Dopamine receptors are distributed in several areas of the brain and are pharmacologically targeted, in order to treat psychosis by decreasing their activity or Parkinson's disease by increasing their activity.

Like most GPCRs, they have been shown to behave like homodimers and heterodimers (Maggio et al., 2008, 2015). As previously explained, SB269652 and its derivatives exert their preeminent allosteric effect on dopamine receptors across dimers. Given that their allosteric effect is strictly dependent on the fraction of receptor dimers in respect to the fraction of monomers, in fact, these compounds would exert a negative modulatory effect only on receptors dimers, and a competitive antagonism only on receptor monomers. Regarding GPCR dimerization, mounting evidence indicates that it is a dynamic process, whereby receptors show a monomer-dimer equilibrium characterized by rapid association and dissociation processes (Scarselli et al., 2013, 2016). In a recent work, Tabor et al. (2016) have shown that the percentage of interacting dopamine D₂ and D₃ receptors is strictly dependent on their concentrations on the plasma membrane and that agonists but not antagonists increase D₂ or D₃ receptor dimerization. In particular, they calculated that, at expression levels comparable to those detected in the caudate and putamen, *in vivo* (Boyson et al., 1986), the percentage of dopamine D₂ receptor dimers compared to monomers was about 20%. Therefore, bitopic compounds would act as competitive antagonists on the 80% of the receptors and as allosteric modulators on the remaining 20%. In comparison, if it is considered that in other parts of the brain, like the limbic system (ventral striatum) and the cortex, dopamine receptor levels are considerably lower (Hall et al., 1994), and so the percentage of receptor dimers, the chances of an allosteric type of behavior for these bitopic compounds would dramatically decrease in comparison with the caudate/putamen. As also explained in the review of Conn et al. (2009), one of the advantages of allosteric modulators with limited negative cooperativity, is that they would impose a ‘ceiling’ on the magnitude of their pharmacological effects. In fact, this property would allow a high degree of titratability for these compounds, which could be administered at large doses with minor side effects if compared to large administered doses of orthosteric ligands.

Moreover, because it is commonly accepted that blocking D₂ receptor activity in the ventral striatum is responsible for the therapeutic antipsychotic effects and blocking the same receptors in the caudate/putamen is responsible for unwanted motor side effects (Jones and Pilowsky, 2002); drugs that are able to target these areas of the brain differently might lead to the development of novel pharmacological tools for the treatment of psychosis. We might then speculate that bitopic drugs acting as allosteric modulators across dimers may be able to discriminate between regions of the brain containing different percentages of dopamine receptor dimers. As a consequence, allosteric modulators in the caudate/putamen, setting a ceiling in the magnitude of their pharmacological effects for this area, could result in a reduction of their motor side effects and thus an increase in their tolerance.

Importantly, as demonstrated by Tabor et al. (2016), agonists promote dopamine receptor dimer formation. Therefore, increases in dopamine levels would result in increases in the percentage of dopamine receptor dimers, which would make bitopic drugs with a negative modulatory effect across dimers, even safer.

Consistent with this concept, the [³⁵S]GTPγS recruitment data in Silvano's paper could be explained by the inability of 1 μM dopamine and the ability of 10 μM dopamine to generate enough dopamine receptor dimers on which SB269652 could direct its allosteric effects (Silvano et al., 2010).

To this purpose, it is interesting to mention that the only *in vivo* data available with SB269625 were published in an abstract form long before the compound was recognized to be allosteric (Taylor et al., 1999). SB269652 was shown to have no effect on the basal release of dopamine in the striatum and nucleus accumbens, but it prevented the inhibition of dopamine release induced by the D₂/D₃ agonist quinelorane in the nucleus accumbens but not in the striatum. These data clearly indicate that the activity of SB269652 has a brain regional selectivity. This regional selectivity cannot be attributed, as originally it was assumed, to the preferential antagonism of this compound at D₃ receptor, as D₃ receptors have a marginal role in regulating dopamine release in respect to D₂ receptor (Joseph et al.,

2002). Furthermore, SB269652 showed no effect on amphetamine-induced hyperactivity, and, in contrast to the orthosteric antagonist haloperidol, it did not induce catalepsy, suggesting that this compound may be devoid of side-effects normally associated with orthosteric dopamine receptor antagonists (Taylor et al., 1999).

In contrast to bitopic compounds that exert their negative allosteric effect across dimers, allosteric compounds that exert negative modulatory effect on the monomer would not be influenced by receptor dimerization. In this case, differences in receptor concentration among areas of the brain should not influence their allosteric properties. Even though pure allosteric modulators would behave in the same way, regardless of tissue-specific receptor dimerization, they would be good drugs anyway, because of the physiological ceiling effects imposed by their intrinsic nature.

Allosteric drugs as new antipsychotic agents

One of the main disadvantages in the use of first-generation antipsychotics is that when occupancy of the dopamine D₂ receptors in the caudate/putamen reaches 75-80%, extrapyramidal side effects start to appear. Nevertheless, this critical point of receptor occupancy of 60-80% should be reached in other area of the brain, such as the limbic system and the cortex, in order to obtain a therapeutic effect (Kasper et al., 1999; Remington and Kapur, 1999; Kapur et al., 2000). As a consequence, clinicians have to titrate the dosage of antipsychotics directly on patients in order to stay in such a narrow therapeutic range of receptor occupancy, a “gamble” that often leads to poor adherence to antipsychotic prescriptions (Haddad et al., 2014).

Unfortunately, even the second generation of antipsychotic drugs, which have additional effects on serotonin receptors (mostly 5HT_{2A} type) and therefore need a reduced D₂ dopamine receptor occupancy to be effective, were not extrapyramidal side effect-free (Rummel-Kluge et al., 2010). In particular, the severity of extrapyramidal side effects varies in relation to the particular second-generation agent used

(with clozapine having the lowest risk and risperidone the highest) and its dosage; the higher the dose, the more intense the extrapyramidal side effects are, which indicates that the safety of these second generation drugs depends on the level of receptor occupancy (Divac et al., 2014).

The antipsychotic aripiprazole seems to have lower propensity for extrapyramidal side effects. Even at low doses, aripiprazole reaches receptor occupancy of 85% without inducing dystonia and parkinsonism, which are conversely observed for higher striatal occupancy (>90%) (Mamo et al., 2007). The lack of dystonia and Parkinsonism is attributed to its partial agonist properties that prevent complete receptor inactivation, but as described above, other mechanisms are probably responsible for it (Mailman and Murthy, 2010). Nevertheless, akathisia is one of aripiprazole's most frequent and troublesome extrapyramidal side effects, being present in approximately 15-25% of patients with schizophrenia and bipolar mania taking the drug (Fleischhacker, 2005; Kinghorn and McEvoy, 2005; Poyurovsky, 2010).

Given the arguments above, the need for new antipsychotic drugs showing minor or no extrapyramidal side effects is evident. Since targeting dopamine D₂ receptors still remains the main strategy to reduce psychotic symptoms, an alternative way to target these receptors could be the use of allosteric compounds. As discussed above, allosteric drugs with modest negative cooperativity have a ceiling effect that should allow physiological adaptation of dopamine neurotransmission to overcome their block and prevent the onset of extrapyramidal side effects.

Furthermore, the hypothetical higher dopamine receptor dimerization in caudate/putamen in respect to other areas of the brain should further improve the benefit/risk profile of compounds with bitopic properties that exert the allosteric effect only on receptor dimers. As a matter of fact, Wang et al. (2010) found a significantly enhanced expression of dopamine D₂ receptor dimers and decreased expression of D₂ receptor monomers in the postmortem striatal tissue of schizophrenic patients (Wang et al., 2010). Furthermore, they demonstrated that treatment of rats with amphetamine, a drug that

increases dopamine concentration in the synaptic cleft, increased D₂ dopamine receptor dimerization in the striatum, while the antipsychotic haloperidol did not alter D₂ dimer levels (Wang et al., 2010). These data are in good agreement with the study in vitro of Tabor et al. (2016) and they support the concept that bitopic drugs with allosteric effect across dimers could have a profound impact on the development of novel and more safe antipsychotic therapies.

Until now, SB269652 remains unique in its mechanism of action, as no other bitopic ligands have been reported to have an allosteric effect across dimers. Nevertheless, allosterism across dimers has been reported for ligands that bind to the orthosteric site of GPCRs homo- and heteromers (Smith and Milligan, 2010). Recently, Bonaventura et al. (2015) described a novel unsuspected allosteric mechanism within the adenosine A_{2A}-dopamine D₂ receptor heteromer by which either orthosteric A_{2A} agonists or antagonists decrease the affinity and intrinsic efficacy of dopamine D₂ agonists and the affinity of D₂ antagonists. They explained these data by a model that considers A_{2A}-D₂ heteromers as heterotetramers, constituted of A_{2A} and D₂ homodimers, and demonstrated that allosteric effects depend on the integrity of the right quaternary structure of the heterotetramer. This was shown in transfected mammalian cells and striatal tissue, by using heteromer-disrupting mutations and transmembrane peptides intercalating between receptors, respectively. The peculiarity of this study was to uncover the negative allosteric modulation of orthosteric A_{2A} antagonists on D₂ receptors, challenging the traditional view that antagonists are inactive ligands. This new reported mechanism of allosterism across adenosine A_{2A}-dopamine D₂ receptor heteromers offers a new target to be investigated in developing drugs with antipsychotic effect, which, as stated in this review many times, should show a drastic reduction of side-effect symptoms because of their allosteric nature.

Concluding remarks

The last ten years have witnessed an explosion in the amount of work done on allosteric modulation of GPCRs. Muscarinic (Jakubík and El-Fakahany, 2010), glutamate (Lundström et al., 2016) and adenosine (Romagnoli et al., 2015) are only some of the receptors that have been widely explored to find allosteric drugs. At the moment, only two allosteric compounds for GPCRs have been approved for marketing, cinacalcet, a positive allosteric modulator of the calcium sensing receptor which is used in hyperparathyroidism, and maraviroc, a negative allosteric modulator of chemokine receptor 5 that is used in the treatment of HIV infections. The experience in using these drugs is still somewhat limited; nevertheless they are a proof of concept that allosteric compounds for GPCRs can be used as therapeutic agents in clinic.

Schizophrenia is a chronic disease and the treatment with the currently available drugs is often troublesome because of the difficulty obtaining a good therapeutic effect without serious collateral side effects. For these reasons, allosteric drugs are good candidates to overcome these problems, at least in part. Indeed, SB269652 is the first negative allosteric modulator of dopamine D₂ and D₃ receptors, and the search for optimized analogues has led to more potent bitopic modulators and pure allosteric drugs. While it is difficult to predict whether allosteric drugs at dopamine receptors will have the same efficacy of the classic orthosteric drugs, their therapeutic potential stands on a solid preclinical background, and it is worth the effort to design optimized derivatives of SB269652 to explore their efficacy in clinic.

In conclusion, compared to the orthosteric-targeted ligands, allosteric molecules show increased specificity for particular GPCR subunits and reduced side effects. Although difficult to develop, allosteric modulators represent one of the most valuable pharmaceutical tools for the development of potent and more selective therapeutic strategies for the treatment of a variety of pathologies.

Acknowledgments

This research was supported in part by the intramural research program of NIH, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Authorship Contribution

Wrote or contributed to the writing of the manuscript: Rossi, Fasciani, Marampon, Maggio, Scarselli.

References

Aloisi G, Silvano E, Rossi M, Millan MJ, and Maggio R (2011) Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: Parallel observations from co-transfected human and native cerebral receptors. *Neuropharmacology* **60**: 439–445.

Ban TA (2007) Fifty years chlorpromazine: a historical perspective. *Neuropsychiatr Dis Treat* **3**: 495–500.

Bonaventura J, Navarro G, Casadó-Anguera V, Azdadk K, Reab W, Moreno E, Brugarolas M, Mallol J, Canela EI, Lluís C, Cortés A, Volkow ND, Schiffmann SN, Ferré S, and Casadó V (2015) Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer. *Proc Natl Acad Sci USA* **112**: 3609-3618.

Boyson SJ, McGonigle P, and Molinoff PB (1986) Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain. *J Neurosci* **6**: 3177–3188.

Carrillo JJ, Pediani J, and Milligan G (2003) Dimers of class A G protein-coupled receptors function via agonist-mediated trans-activation of associated G proteins. *J Biol Chem* **278**: 42578–42587.

Chien EY, Liu W, Zhao Q, Katritch V, Han GW, Hanson MA, Shi L, Newman AH, Javitch JA, Cherezov V, and Stevens RC (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. *Science* **330**: 1091–1095.

Conn PJ, Christopoulos A, and Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. *Nat Rev Drug Discov* **8**: 41–54.

Divac N, Prostran M, Jakovcevski I, and Cerovac N (2014) Second-generation antipsychotics and extrapyramidal adverse effects. *Biomed Res Int* **2014**: 656370.

Ferre S, Casado V, Devi LA, Filizola M, Jockers R, Lohse MJ, Milligan G, Pin JP, and Guitart X (2014) G protein-coupled receptor oligomerization revisited: Functional and pharmacological perspectives. *Pharmacol Rev* **66**: 413–434.

Fiorentini C, Busi C, Gorruso E, Gotti C, Spano P, and Missale C (2008) Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. *Mol Pharmacol* **74**: 59–69.

Fleischhacker WW (2005) Aripiprazole. *Expert Opin Pharmacother* **6**: 2091–2101.

Furman CA, Roof RA, Moritz AE, Miller BN, Doyle TB, Free RB, Banala AK, Paul NM, Kumar V, Sibley CD, Newman AH, and Sibley DR (2015) Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists. *Eur Neuropsychopharmacol* **25**: 1448–1461.

Gil-Mast S, Kortagere S, Kota K, and Kuzhikandathil EV (2013) An amino acid residue in the second extracellular loop determines the agonist-dependent tolerance property of the human D3 dopamine receptor. *ACS Chem Neurosci* **4**: 940–951.

Haddad PM, Brain C, and Scott J (2014) Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. *Patient Relat Outcome Meas* **5**: 43–62.

Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, and Farde L (1994) Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. *Neuropsychopharmacology* **11**: 245–256.

Hamon J, Paraire J, and Velluz J (1952) Remarques sur l'action du 4560 RP sur l'agitation maniaque. *Ann Med Psychol (Paris)* **110**: 331–335.

Jakubík J, and El-Fakahany EE (2010) Allosteric modulation of muscarinic acetylcholine receptors. *Pharmaceuticals* **3**: 2838–2860.

Jakubík J, Zimčík P, Randáková A, Fuksová K, El-Fakahany EE, and Doležal V (2014) Molecular mechanisms of methoctramine binding and selectivity at muscarinic acetylcholine receptors. *Mol Pharmacol* **86**: 180–192.

Jones HM, and Pilowsky LS (2002) Dopamine and antipsychotic drug action revisited. *Br J Psychiatry* **181**: 271-275.

Joseph JD, Wang YM, Miles PR, Budygin EA, Picetti R, Gainetdinov RR, Caron MG, Wightman RM (2002) Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors. *Neuroscience* **112**: 39-49.

Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, and Seeman P (2000) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. *Arch Gen Psychiatry* **57**: 553–559.

Kasper S, Tauscher J, Küfferle B, Barnas C, Pezawas L, and Quiner S (1999) Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia. *Eur Arch Psychiatry Clin Neurosci* **249**: 83–89.

Keck PE Jr, and McElroy SL (2003) Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. *Expert Opin Investig Drugs* **12**: 655-662.

Keck TM, Burzynski C, Shi L, and Newman AH (2014) Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design. *Adv Pharmacol* **69**: 267–300.

Kinghorn WA, and McEvoy JP (2005) Aripiprazole: pharmacology, efficacy, safety and tolerability. *Expert Rev Neurother* **5**: 297–307.

Kruse AC, Ring AM, Manglik A, Hu J, Hu K, Eitel K, Hübner H, Pardon E, Valant C, Sexton PM, Christopoulos A, Felder CC, Gmeiner P, Steyaert J, Weis WI, Garcia KC, Wess J, and Kobilka BK (2013) Activation and allosteric modulation of a muscarinic acetylcholine receptor. *Nature* **504**: 101–106.

Lane JR, Donthamsetti P, Shonberg J, Draper-Joyce CJ, Dentry S, Michino M, Shi L, López L, Scammells PJ, Capuano B, Sexton PM, Javitch JA, and Christopoulos A (2014) A new mechanism of allostery in a G protein-coupled receptor dimer. *Nat Chem Biol* **10**: 745–752.

Lee SP, So CH, Rashid AJ, Varghese G, Cheng R, Lanca AJ, O'Dowd BF, and George SR (2004) Dopamine D1 and D2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. *J Biol Chem* **279**: 35671–35678.

Lundström L, Bissantz C, Beck J, Dellenbach M, Woltering TJ, Wichmann J, and Gatti S (2016) Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2. *Neuropharmacology* **111**: 253–265.

Maggio R, Innamorati G, and Parenti M (2007) G protein-coupled receptor oligomerization provides the framework for signal discrimination. *J Neurochem* **103**: 1741–1752.

Maggio R, Novi F, Rossi M, Corsini GU, and Millan MJ (2008) Partial agonist actions at dopamine D2L receptors are modified by co-transfection of D3 receptors: potential role of heterodimer formation. *Parkinsonism Relat Disord* **14**: S139-S144.

Maggio R, Rocchi C, and Scarselli M (2013) Experimental strategies for studying G protein-coupled receptor homo- and heteromerization with radioligand binding and signal transduction methods. *Methods Enzymol* **521**: 295–310.

Maggio R, Scarselli M, Capannolo M, and Millan MJ (2015) Novel dimensions of D3 receptor function: Focus on heterodimerization, transactivation and allosteric modulation. *Eur Neuropsychopharmacol* **25**: 1470–1479.

Mailman RB, and Murthy V (2010) Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? *Curr Pharm Des* **16**: 488–501.

Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, and Kapur S (2007) Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. *Am J Psychiatry* **164**: 1411–1417.

May LT, Leach K, Sexton PM, and Christopoulos A (2007) Allosteric modulation of G protein–coupled receptors. *Annu Rev Pharmacol Toxicol* **47**: 1–51.

Meltzer HY (2012) Clozapine: balancing safety with superior antipsychotic efficacy. *Clin Schizophr Relat Psychoses* **6**: 134-144.

Meltzer HY, and Massey BW (2011) The role of serotonin receptors in the action of atypical antipsychotic drugs. *Curr Opin Pharmacol* **11**: 59-67.

Missale C, Nash SR, Robinson SW, Jaber M, and Caron MG (1998) Dopamine receptors: from structure to function. *Physiol Rev* **78**: 189–225.

Mistry SN, Shonberg J, Draper-Joyce CJ, Klein Herenbrink C, Michino M, Shi L, Christopoulos A, Capuano B, Scammells PJ, and Lane JR (2015) Discovery of a novel class of negative allosteric modulator of the dopamine D2 receptor through fragmentation of a bitopic ligand. *J Med Chem* **58**: 6819–6843.

Pou C, Mannoury la Cour C, Stoddart LA, Millan MJ, and Milligan G (2012) Functional homomers and heteromers of dopamine D2L and D3 receptors co-exist at the cell surface. *J Biol Chem* **287**: 8864–8878.

Poyurovsky M (2010) Acute antipsychotic-induced akathisia revisited. *Br J Psychiatry* **196**: 89–91.

Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, Hadley MS, Hunter AJ, Jeffrey P, Jewitt F, Johnson CN, Jones DN, Medhurst AD, Middlemiss DN, Nash DJ, Riley GJ, Routledge C, Stemp G, Thewlis KM, Trail B, Vong AK, and Hagan JJ (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. *J Pharmacol Exp Ther* **294**: 1154–1165.

Remington G, and Kapur S (1999) D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. *J Clin Psychiatry* **60**: 15–19.

Romagnoli R, Baraldi PG, Moorman AR, Borea PA, and Varani K (2015) Current status of A1 adenosine receptor allosteric enhancers. *Future Med Chem* **7**: 1247–1259.

Rossi M, Dimida A, Ferrarini E, Silvano E, De Marco G, Agretti P, Aloisi G, Simoncini T, Di Bari L, Tonacchera M, Giorgi F, and Maggio R (2009) Presence of a putative steroidal allosteric site on glycoprotein hormone receptors. *Eur J Pharmacol* **623**: 155–159.

Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, and Leucht S (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. *Schizophr Res* **123**: 225–233.

Salmas RE, Yurtsever M, and Durdagi S (2016) Atomistic molecular dynamics simulations of typical and atypical antipsychotic drugs at the dopamine D2 receptor (D2R) elucidates their inhibition mechanism. *J Biomol Struct Dyn* **6**: 1–17.

Scarselli M, Annibale P, Gerace C, and Radenovic A (2013) Enlightening G-protein-coupled receptors on the plasma membrane using super-resolution photoactivated localization microscopy. *Biochem Soc Trans* **41**: 191–196.

Scarselli M, Annibale P, McCormick PJ, Kolachalam S, Aringhieri S, Radenovic A, Corsini GU, and Maggio R (2016) Revealing G-protein-coupled receptor oligomerization at the single-molecule level through a nanoscopic lens: methods, dynamics and biological function. *FEBS J* **283**: 1197–1217.

Scarselli M, Novi F, Schallmach E, Lin R, Baragli A, Colzi A, Griffon N, Corsini GU, Sokoloff P, Levenson R, Vogel Z, and Maggio R (2001) D2/D3 dopamine receptor heterodimers exhibit unique functional properties. *J Biol Chem* **276**: 30308–30314.

Shonberg J, Draper-Joyce C, Mistry SN, Christopoulos A, Scammells PJ, Lane JR, and Capuano B (2015) Structure-activity study of N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652), a bitopic ligand that acts as a negative allosteric modulator of the dopamine D2 receptor. *J Med Chem* **58**: 5287–5307.

Silvano E, Millan MJ, Mannoury la Cour C, Han Y, Duan L, Griffin SA, Luedtke RR, Aloisi G, Rossi M, Zazzeroni F, Javitch JA, and Maggio R (2010) The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors. *Mol Pharmacol* **78**: 925–934.

Smith NJ and Milligan G (2010) Allosterism at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. *Pharmacol Rev* **62**: 701–725.

Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, and Burris KD (2007) Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies. *Psychopharmacology (Berl)* **190**: 373-382.

Stemp G, Ashmeade T, Branch CL, Hadley MS, Hunter AJ, Johnson CN, Nash DJ, Thewlis KM, Vong AK, Austin NE, Jeffrey P, Avenell KY, Boyfield I, Hagan JJ, Middlemiss DN, Reavill C, Riley GJ, Routledge C, Wood M (2000) Design and synthesis of trans- N-[4-[2-(6-Cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat. *J Med Chem* **43**: 1878–1885.

Tabor A, Weisenburger S, Banerjee A, Purkayastha N, Kaindl JM, Hübner H, Wei L, Grömer TW, Kornhuber J, Tschammer N, Birdsall NJ, Mashanov GI, Sandoghdar V, Gmeiner P (2016) Visualization and ligand-induced modulation of dopamine receptor dimerization at the single molecule level. *Sci Rep* **6**: 33233.

Taylor SG, Riley G, Hunter AJ, Stemp G, Routledge C, Hagan JJ, Reavill C (1999) SB-269652 is a selective D3 receptor antagonist in vitro and in vivo. *Eur Neuropsychopharm* **9**: S266.

Wang M, Pei L, Fletcher PJ, Kapur S, Seeman P, and Liu F (2010) Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization. *Mol Brain* **3**: 25.

Wood M, Ates A, Andre VM, Michel A, Barnaby R, and Gillard M (2016) In vitro and in vivo identification of novel positive allosteric modulators of the human dopamine D2 and D3 receptor. *Mol Pharmacol* **89**: 303–312.

Figure legends

Figure 1

Schematic representation of the allosteric binding mode of SB269652 to dopamine receptor dimer and monomer. SB269652 is represented with its three main parts, the 7CN-THIQ group (pink), the trans-cyclohexylene spacer in the middle and the indole-2-carboxamide tail (sky blue). In the left part of the image, SB269652 is shown binding in a bitopic mode to one protomer of the dopamine dimer, the 7CN-THIQ group to the orthosteric site (Orth) and the indole-2-carboxamide group to the allosteric site (All1), and exerting an allosteric effect across dimer on dopamine sitting on the orthosteric site of the other protomer (Lane *et al.*, 2014). In the right part of the image, SB269652 is shown binding to a dopamine occupied monomer and preventing the dissociation of dopamine from the same receptor. In this configuration, the indole-2-carboxamide group would bind to the allosteric site as shown for SB269652 in the bitopic pose (All1), while the 7CN-THIQ group would engage an additional site on the extracellular part of the receptor (All2). This second arrangement of SB269652 on the dopamine-occupied receptor would be unfavorable respect to the bitopic binding mode, and it would occur only for high doses of the drug.

Figure 2

Chemical structure of optimized SB269652 analogues. Value of K_B (functional affinity) and $\alpha\beta$ (allosteric cooperativity with dopamine) were taken from Shonberg *et al.* (2015) and Mistry *et al.* (2015). The part of the molecule boxed in pink binds to the orthosteric site while the part boxed in light blue binds to the allosteric site. For comparison we added a compound (25d) lacking an allosteric effect.

Figure 1




Figure 2

